While tirzepatide shows promise as a treatment for NAFLD, it is essential to adopt a comprehensive approach to liver health management
doi: 10.1111/j.0105-2896.2009.00859.x 188 BeyerKLieSABjorndalBBergeRKSvardalABrunJGet al
A recent meta-analysis of randomized controlled trials (RCTs), including AMPLITUDE-O, examining six GLP-1 receptor agonists (lixisenatide, liraglutide, subcutaneous semaglutide, exenatide, dulaglutide, and efpeglenatide) reported a 21% reduction in a composite kidney outcome (macroalbuminuria, doubling of serum creatinine or 40% eGFR decline, RRT, or death from kidney disease), corresponding to a number needed to treat of 47 [73]
CPT1 is a mitochondrial importer of fatty acids
USD OZEM Only available to USA clients through the Kraken app or Kraken Pro